ISRCTN14732774已完成不适用
Adoptive immunotherapy for adenovirus (AdV)-associated complications post transplantatio
Charité - University Medicine Berlin (Germany)0 个研究点目标入组 306 人开始时间: 2006年3月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 306
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Pediatric patients, aged 2 to 18 years with:
- •1. Acute leukemias (ALL)
- •2. Acute myeloid leukemia (AML)
- •3. Chronic myeloid leukemia (CML)
- •4. Myelodysplastic syndromes (MDS)
排除标准
- •1. Patients in relapse or progress of AML or ALL and blast crisis of CML at the time of randomization
- •2. All second transplants
- •3. AdV seronegative recipients with seronegative matched related donors (MRD)
- •4. Patients with severe non-hematopoietic organ toxicity grade 3-5 (according to the National Cancer Institute [NCI] and Cancer Therapy Evaluation Program [CTEP] reporting criteria) at the time of randomization
研究者
相似试验
进行中（未招募）
不适用
Adoptive Immuntherapie der akuten ADV-Infektion nach allogener Knochenmark- oder peripherer Blutstammzelltransplantation - ÎAKSAdenovirus infection following allogeneic stem cell transplantation.EUCTR2005-001092-35-DE
已完成
不适用
Oncolytic adenovirus therapy as an adjuvant treatment for localised prostate cancer.Prostate carcinoma1003859710036958prostate cancerNL-OMON43563Erasmus MC, Universitair Medisch Centrum Rotterdam18
尚未招募
不适用
Oncolytic adenovirus therapy as an adjuvant treatment for localised prostate cancer.Oncolytic adenovirus therapy, Localised prostate cancer, Adjuvant treatment, Radical prostatectomyOncolytische adenovirus therapie, Gelokaliseerde prostaatkanker, Adjuvante behandeling, Radicale prostatectomieNL-OMON24928Erasmus MC18
已完成
1 期
Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCTADV Infection Post Allo-HSCTNCT01822093Cell Medica Ltd8
撤回
1 期
Virus-specific ImmunoTherapy Following Allogeneic Stem Cell TransplantationAdenovirus InfectionCytomegalovirus InfectionNCT02702427St. Anna Kinderkrebsforschung